Prerequisites for a dry powder inhaler for children with cystic fibrosis.

by Anne J Lexmond, Paul Hagedoorn, Henderik W Frijlink, Bart L Rottier, Anne H de Boer
Published 2017-01-01

Effect of inhaler design variables on paediatric use of dry powder inhalers.

by Anne J Lexmond, Tonnis J Kruizinga, Paul Hagedoorn, Bart L Rottier, Henderik W Frijlink, Anne H de Boer
Published 2014-01-01

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

by Floris Grasmeijer, Anne J Lexmond, Maarten van den Noort, Paul Hagedoorn, Anthony J Hickey, Henderik W Frijlink, Anne H de Boer
Published 2014-01-01

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma

by Fajri Gafar, Ilse M. Boudewijn, Claire A. Cox, Judith M. Vonk, Siebrig Schokker, Anne J. Lexmond, Henderik W. Frijlink, Paul Hagedoorn, Dirkje S. Postma, Maarten van den Berge
Published 2018-12-01

Targeting the small airways with dry powder adenosine: a challenging concept

by Erica van der Wiel, Anne J. Lexmond, Maarten van den Berge, Dirkje S. Postma, Paul Hagedoorn, Henderik W. Frijlink, Martijn P. Farenhorst, Anne H. de Boer, Nick H. T. ten Hacken
Published 2017-01-01

Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma

by Claire A. Cox, Ilse M. Boudewijn, Sebastiaan J. Vroegop, Siebrig Schokker, Anne J. Lexmond, Henderik W. Frijlink, Paul Hagedoorn, Judith M. Vonk, Martijn P. Farenhorst, Nick H. T. ten Hacken, Huib A. M. Kerstjens, Maarten van den Berge
Published 2019-01-01